Takeda Pharmaceutical Company Limited (TAK): Price and Financial Metrics


Takeda Pharmaceutical Company Limited (TAK): $17.00

-0.22 (-1.28%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add TAK to Watchlist
Sign Up

Industry: Biotech


Ranked

of 505

in industry

TAK POWR Grades


  • TAK scores best on the Value dimension, with a Value rank ahead of 98.84% of US stocks.
  • The strongest trend for TAK is in Momentum, which has been heading down over the past 48 weeks.
  • TAK ranks lowest in Momentum; there it ranks in the 13th percentile.

TAK Stock Summary

  • Price to trailing twelve month operating cash flow for TAK is currently 0.05, higher than merely 1.12% of US stocks with positive operating cash flow.
  • The volatility of Takeda Pharmaceutical Co Ltd's share price is greater than that of merely 2.69% US stocks with at least 200 days of trading history.
  • Takeda Pharmaceutical Co Ltd's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is 1,596.53%, greater than the shareholder yield of 99.65% of stocks in our set.
  • If you're looking for stocks that are quantitatively similar to Takeda Pharmaceutical Co Ltd, a group of peers worth examining would be TEL, BSX, IFF, PHG, and CTVA.
  • Visit TAK's SEC page to see the company's official filings. To visit the company's web site, go to www.takeda.com.

TAK Stock Price Chart Interactive Chart >

Price chart for TAK

TAK Price/Volume Stats

Current price $17.00 52-week high $19.97
Prev. close $17.22 52-week low $15.30
Day low $16.98 Volume 1,503,200
Day high $17.19 Avg. volume 2,694,491
50-day MA $16.81 Dividend yield 3.95%
200-day MA $17.39 Market Cap 53.80B

Takeda Pharmaceutical Company Limited (TAK) Company Bio


Takeda Pharmaceutical Company Limited is engaged in research and development, manufacturing, sales and marketing, and import and export of pharmaceutical drugs. The Company focuses on the core therapeutic areas of oncology, gastrointestinal, and central nervous system disease.


TAK Latest News Stream


Event/Time News Detail
Loading, please wait...

TAK Latest Social Stream


Loading social stream, please wait...

View Full TAK Social Stream

Latest TAK News From Around the Web

Below are the latest news stories about Takeda Pharmaceutical Co Ltd that investors may wish to consider to help them evaluate TAK as an investment opportunity.

Takeda Agrees With Mirum Pharma For Approval, Commercialization Of Maralixibat In Japan

(RTTNews) - Mirum Pharmaceuticals, Inc. (MIRM) and Takeda Pharmaceutical Company Limited (TAK) have entered into an exclusive licensing agreement for the development and commercialization of maralixibat in Japan for Alagille syndrome, progressive familial intrahepatic cholestasis, and biliary atresia. Under the agreement, Takeda will be

Business Insider Markets | September 21, 2021

Mirum, Takeda Ink Maralixibat Licensing Pact In Japan

Mirum Pharmaceuticals Inc (NASDAQ: MIRM) and Takeda Pharmaceutical Company Limited (NYSE: TAK) have entered into an exclusive licensing agreement for maralixibat in Japan for Alagille syndrome (ALGS), progressive familial intrahepatic cholestasis (PFIC), and biliary atresia (BA). Under the terms of the agreement, Takeda will be responsible for regulatory approval and commercialization of maralixibat in Japan. Takeda will also be responsible for the development, including conducting clinical stud

Yahoo | September 21, 2021

Mirum Pharmaceuticals and Takeda Enter into Exclusive Licensing Agreement to Develop and Commercialize Maralixibat for Rare Pediatric Liver Diseases in Japan

FOSTER CITY, Calif. & OSAKA, Japan, September 21, 2021--Mirum and Takeda Enter into Exclusive Licensing Agreement to Develop and Commercialize Maralixibat for Rare Pediatric Liver Diseases in Japan

Yahoo | September 21, 2021

Global Rubella Treatment Market Valuable Growth Prospects, Top Players, Key Country Analysis, Trends and Forecast till 2028||Dr. Reddys Laboratories Ltd, Aurobindo Pharma, Sun Pharmaceutical Industries Ltd, GlaxoSmithKline plc, Takeda Pharmaceutical Co

Advanced report on Rubella Treatment Market Added by Data Bridge Market Research, offers details on current and future growth trends pertaining to the business besides information on myriad regions across the geographical landscape of the Rubella Treatment

OpenPR | September 20, 2021

Exkivity: US approves drug for lung cancer

Takeda Pharmaceutical said on Wednesday the US Food and Drug Administration approved its drug, Exkivity, to treat a type of lung cancer. Takeda said the approval was based on an early-to-mid-stage trial testing 114 patients with non-small cell lung cancer, with results showing clinically meaningful responses with a median duration of about 18 months. Exkivity [] The post Exkivity: US approves drug for lung cancer appeared first on ARY NEWS .

ARY News | September 16, 2021

Read More 'TAK' Stories Here

TAK Price Returns

1-mo 0.06%
3-mo 0.65%
6-mo -11.37%
1-year -6.79%
3-year -14.76%
5-year -24.82%
YTD -6.59%
2020 -5.97%
2019 19.31%
2018 -40.08%
2017 36.91%
2016 -16.98%

TAK Dividends

Ex-Dividend Date Type Payout Amount Change
Loading, please wait...
View Full TAK Dividend History

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 1.04 seconds.